Merck & Co., Inc. (MRK)[Tv]

Key Developments

• FDA approval of Lipfendra (enlicitide), the first oral PCSK9 inhibitor, marks a transformative milestone in cardiovascular medicine, signaling Merck’s strategic pivot beyond oncology and unlocking a high-margin, first-in-class franchise with blockbuster potential.
• Expanded FDA approval of Keytruda in combination with Padcev for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer—now including cisplatin-eligible patients—extends Keytruda’s reach, reinforces its leadership in combination immuno-oncology, and provides a critical hedge against the looming 2028 patent cliff.
• Launch of generic Janumet® XR by Par Health directly erodes approximately $270 million in annual U.S. revenue, underscoring Merck’s vulnerability to generic competition despite its oncology dominance.
• Critical 47% downward revision in Zacks Consensus EPS estimate for 2026, now forecasting a negative EPS of -$0.26, exposes deep earnings deterioration and contradicts optimistic Wall Street ratings, signaling fragility in market confidence.
• Ongoing U.S. House Select Committee investigation into Merck’s clinical trial activities in Xinjiang and military-affiliated hospitals poses an existential geopolitical risk, threatening regulatory trust, global operations, and long-term investor sentiment.